New York, N.Y.—November 18, 2008—InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced the U.S. release of its next generation hypertension treatment device, RESPeRATE Ultra. The new product, which incorporates new interactive features and a simpler user experience in just half the size of previous models, will be initially sold through www.resperate.com at a price of $349.95.

The RESPeRATE Ultra was designed with input from thousands of RESPeRATE users. Featuring a large, enhanced display, fewer buttons and simple menus, the unit was crafted to not only provide the same blood pressure reduction results as its predecessor, but also provide an enhanced, pleasurable device-guided breathing experience. The RESPeRATE Ultra also includes a first-of-its-kind interactive tutorial that guides the user to quickly learn to use the device to most effectively lower his or her blood pressure.

“RESPeRATE Ultra is truly our smartest device ever, delivering all of the power of our previous models, but with a dramatically enhanced user interface and small, sleek, portable design,” said Erez Gavish, president and CEO of InterCure. “We have sold well over 100,000 RESPeRATE devices, most of them one at a time directly to consumers. We continuously reach out to our users to ask how our product can be improved. RESPeRATE Ultra is the result of this feedback and represents a new level of sophisticated design. With the Ultra, we have delivered the technological equivalent of a personal breathing coach, with the intelligence to maximize your blood pressure reductions naturally, without side effects.”

RESPeRATE Ultra will be available in the U.S. directly from InterCure beginning today (see http://www.resperate.com/us/shop/home.aspx) and will roll out to its e-commerce and retail customers in 2009.

RESPeRATE® products are FDA-cleared for over-the-counter sale and are the only medical devices on the market clinically-proven to lower blood pressure through paced breathing therapy. The devices use the body’s natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a “therapeutic zone” of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world’s first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.

RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device’s efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.

With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world’s most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.

InterCure has an exciting product pipeline based on its broadly-patented “Device-Guided Breathing” technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.

Forward-Looking Statements
This news release may contain forward-looking statements that are based on the Company’s current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.